Peer-influenced content. Sources you trust. No registration required. This is HCN.

Oncology News Central (ONC)Osimertinib Plus Chemo Now First-Line Standard in EGFR-Mutated NSCLC?

New FLAURA2 Data Suggests Enhanced PFS but at the Cost of Increased Toxicity

The FLAURA2 clinical trial has revealed that a combination of osimertinib and chemotherapy could be good news for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). However, the increased progression-free survival (PFS) comes with a higher rate of adverse events, sparking debate among experts about the risk-benefit ratio of this new treatment approach.

HCN Medical Memo
The FLAURA2 data presents a compelling but complex picture. Although the combination of osimertinib and platinum-pemetrexed shows promise in extending PFS, it does so at the cost of increased toxicity. Therefore, the decision to adopt this regimen as a first-line treatment should be made cautiously, weighing the risks and benefits for each individual patient.

Key Points:
  • The FLAURA2 trial showed that patients treated with osimertinib plus platinum-pemetrexed had a 38% reduced risk for death or disease progression compared to osimertinib alone (HR=0.62; 95% CI, 0.49-0.79; P<.0001).
  • Median PFS for the combination therapy was 25.5 months, compared to 16.7 months for osimertinib alone.
  • Dr. Pasi A. Jänne, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, suggests that the combination offers a new first-line treatment option.
  • Dr. Yi-Long Wu of Guangdong Lung Cancer Institute questioned the risk-benefit ratio, citing an increase in grade 3 or worse adverse events from 11% to 53%.

“PFS was consistent for all predefined subgroups in favor of the combination, including patients of different race, EGFR mutation method testing, smoking history, CNS status at baseline, and more.”
– Pasi A. Jänne, MD, Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute in Boston

Additional Points:
  • At 24 months, the PFS rate was 57% for the combination therapy compared to 41% for osimertinib alone.
  • The objective response rate was 83.2% with the combination and 75.5% with monotherapy.
  • Most common adverse events in the combination arm were related to chemotherapy toxicities, including hematologic toxicities and nausea.

More in Lung Cancer

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form